White House: drugmakers commit at least $19.6 billion to U.S. manufacturing
Federal health officials have yet to make public the specific terms of the drug-pricing agreements President Trump announced Monday with nine additional pharmaceutical companies. The undisclosed details include the size of the discounts offered and which drugs they cover, after Health and Human Services Secretary Robert F. Kennedy Jr. said he was willing to release them.
The participating companies have committed to invest at least $19.6 billion in U.S. manufacturing, according to the White House. The agreements tie U.S. drug prices to the lower levels charged in other wealthy nations and include voluntary price reductions on products sold to consumers and the government through the TrumpRx discount website. UPI reported that, in return, many manufacturers would receive breaks on Trump’s tariffs and unspecified additional benefits.
Politico reported that in most of the deals so far, the companies have announced price drops for a subset of their products, which state Medicaid programs can then purchase.
The nine new additions are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB. The agreements bring the total number of participating companies to 26, which Trump said represent 90 percent of the domestic pharmaceutical market, adding that the remaining 10 percent “have no choice” but to join, according to CBS News.